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Abstract
Vascular endothelial growth factor (VEGF) regulates vascular permeability 
and endothelial cell proliferation. In the rat anti-Thy1.1 mesangioproliferative 
nephritis inhibition of VEGF165 impairs glomerular endothelial repair. We now 
studied the effects of systemic overexpression of VEGF165 during glomerular 
endothelial damage in this model. Hepatic gene transfer was performed by tail 
vein injection of a human VEGF165 expression plasmid or LacZ control vector 
24 hours prior to induction of anti-Thy1.1-nephritis. Rats receiving high dose 
VEGF165 (800 μg plasmid; serum levels at 48h 762 ? 434 pg/ml vs. <30 pg/ml in 
LacZ rats) showed generalized edema and transient hypotension on days 0 
and 1, whereas LacZ treated animals remained normotensive. On days 2 
and/or 6 after disease induction, mesangiolysis, glomerular cell proliferation 
and glomerular monocyte/macrophage infiltration was significantly increased in 
high dose VEGF165 rats vs. LacZ rats. Proteinuria on day 6 was 142 ± 29 mg/d 
(VEGF165) vs. 66 ± 41 mg/d (LacZ). Aggravation of glomerular injury was not 
due to altered anti-Thy1.1 antibody binding after VEGF165 gene transfer. Rather, 
a dihydralazine treated control group with sham gene transfer showed that 
systemic hypotension per se augmented glomerular injury. However, hepatic 
overexpression of 8-fold lower VEGF165 doses in anti-Thy1.1-nephritis also 
resulted in augmented damage on day 2 and failed to improve glomerular 
histology on day 6. In summary, contrary to our expectation, VEGF165
overexpression during early anti-Thy1.1 nephritis augmented glomerular injury, 
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possibly mediated by systemic hypotension and/or uncoordinated endothelial 
repair. These findings raise important safety concerns in cases of systemic 
VEGF therapy and concomitant mesangiolytic injury. 
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Introduction
 General Introduction 
The renal glomerulus is a well-developed capillary network and the basic 
filtration organ in the kidney. Circulating plasma is continuously filtrated to yield 
urine. Therefore it is critical to preserve the normal structure of the glomerular
capillaries. It is composed mainly from three types of cells, mesangial cells, 
fenestrated endothelial cells and podocytes [1] (Fig.1). The mesangial cells 
especially function as a fundamental component of glomerular architecture and 
are essential to keep the glomerular capillary lumen open in order to maintain 
efficient ultrafiltration [2].
Figure 1. Mesangial cells, fenestrated endothelial cells and podocytes are
responsible for the glomerular capillary structure. 
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Various degrees of injury to glomerular mesangial cells, endothelial cells 
and thus the glomerular capillary network have been reported in various renal 
diseases such as hemolytic-uremic syndrome, renal transplant rejection, Ig-A 
nephropathy, acute glomerulonephritis and diabetic nephropathy. When the 
cellular components of the glomerular capillary network are damaged, the 
capillary lumen is obliterated leading to the loss of renal function. The glomeruli 
undergo a loss of functioning capillaries and exhibit localized areas of cell 
proliferation and progressive scarring that eventually cause the capillary bed to 
collapse. Mesangiolysis, the following mesangioproliferation and matrix 
accumulation appear to play a significant role in these glomerular diseases. 
Mesangiolysis is defined as ‘dissolution or attenuation of mesangial matrix 
and degeneration of mesangial cells’ [3, 4]. In essence, it is an injurious process, 
which affects the glomerular mesangium without causing obvious damage to 
the capillary basement membranes. The mesangial cells may show only edema 
and vacuolization, or may undergo severe degeneration and necrosis. The 
matrix swells, loosens, and eventually dissolves. Although pathologic changes 
of damaged glomeruli are thought to be irreversible and progressive, some 
glomerular components seem to have recovering potential. 
Glomerular remodeling is a permanent process, even in normal kidney. In 
some human end-stage renal diseases, the normal glomerular structure and 
function can be restored in response to clinical treatment. Within the glomerulus, 
endothelial and mesangial cells exhibit relatively high turnover and thus high 
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capacity to regenerate following injury. Out of the chaotic network of cytokines 
and growth factors some factors have evolved, which exhibit well-defined 
actions in the glomerulus that renders them attractive as targets for 
interventions. These factors include platelet-derived growth factor (PDGF), a 
central mediator of mesangial cell proliferation and matrix synthesis and 
vascular endothelial growth factor (VEGF), a central angiogenic mediator 
regulating endothelial cell proliferation and survival [1]. Understanding the 
mechanisms by which these factors promote glomerular healing after 
mesangiolytic injury can be helpful to establish strategies for successful 
treatment of human glomerular diseases. 
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The anti-Thy 1.1 nephritis: a rat model of mesangioproliferative 
glomerulonephritis
In the glomerulus, mesangial cells are specialized cells located among the 
glomerular capillaries within a renal corpuscle. A 'state of the art' review article 
by Schlöndorff et al. listed their functions as follows [2]: 
1. structural support for the glomerulus, and especially the capillary 
loops 
2. generation and turnover of extracellular mesangial matrix 
3. target site for vasoactive agents such as vasocontrictors 
( angiotensin, endothelin, vasopressin, and norepinephrine) vasodilators 
(atriopeptin, nitric oxide, prostaglandine PGE  and PGI ) and dopamine 2 2
4. target site for inflammatory mediators, growth factors, and 
cytokines with effects on cell proliferation and matrix turnover 
5. site of production of vasoactive mediators and growth modifying 
agents, such as prostaglandins, thromboxane, lipoxygenase products, 
platelet activating factor, nitric oxide, etc. 
6. site of production of various growth factors and cytokines such as 
PDGF, IL-1, CSF-1, TGF-? , etc 
7. expression of chemokines and adhesion molecules 
8. generation of plasminogen activator and inhibitors 
9. handling of macromolecules such as lipids, immune complexes 
 9
and advanced glycation endproducts (AGE). 
Injury to the mesangial cells may result in overshooting proliferation 
followed by pathological deposition of extracellular matrix in many human 
glomerular diseases including IgA nephropathy, membranoproliferative 
glomerulonephritis, lupus nephritis and diabetic nephropathy. To clarify the 
mechanisms involved in these processes, several animal models have been 
developed to simulate mesangioproliferative disease, however, the rat 
anti-Thy1.1 model has been the most widely studied. 
The anti-Thy 1.1 nephritis model is a self-limited disease characterized by 
initial mesangiolysis followed by mesangial cell proliferation and accumulation 
of mesangial matrix with subsequent resolution and return to normal histology 
[5]. (Fig. 2, original data of our laboratory) (Fig. 3 [6]) 
The Thy-1.1 antigen is a glycosyl-phosphatidyl-inositol anchored 
membrane protein found on thymocytes, but also on the surface of mesangial 
cells [5]. The nephritis is induced by injecting rats with complement-fixing 
antibodies raised against the Thy-1.1 antigen. The classic experiments were 
performed either with polyclonal antibodies or with monoclonal antibodies like 
the clone OX-7 [7] that is in use in our laboratory.  
The natural history of this model is one of resolution over a period of 6-8 
weeks; however, progressive disease can be achieved by repeated injections 
of antibody [8] or combining antibody injection with uninephrectomy [9]?leading
to persistent mesangial injury that is more analogous to human disease.
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After injection, the disease course can be divided into several different 
phases including the initial injury, the subsequent mesangial response to injury, 
the accumulation of mesangial matrix and finally the resolution phase (see Fig 
2).
Phase 1: Initial Injury
Following the injection, the anti-Thy 1.1 antibodies bind to the cell surface 
of mesangial cells producing a complement-dependent injury. There is a loss of 
a large proportion of the mesangial cell population and dissolution of mesangial 
matrix (mesangiolysis) occuring over the first 1-48 hours (Fig. 2, A-D). The 
subsequent loss of mesangial support to the glomerular capillary loop results in 
distension of glomerular capillaries and segmental microaneurysmal ballooning 
peaking at day 5 [9] (Fig. 2, E) (Fig. 3, C). Though the capillaries get extensively 
expanded, their branching pattern in conjunction with the folding pattern of the 
glomerular basement membrane (GBM) is largely preserved, associated with 
the maintenance of GBM niches. Mesangial areas expand as well (albeit 
apparently less than the capillaries), contain only few cells, and are almost 
devoid of any structured matrix. Most cells in mesangial areas are 
macrophages[10]. In a descriptive paper by Jefferson et al. [5], the expansion of 
capillaries and mesangial areas resulted in total enlargement of the tuft by 78% 
on day 2. The initial cell death is not only due to complement-dependent cell 
lysis but also to complement-dependent and complement-independent 
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apoptosis [5] . 
A variety of factors including  
1. complement 
2. nitric oxide 
3. reactive oxygen species 
4. basic fibroblast growth factor 
5. infiltrating cells  
have been shown to mediate the initial cell injury.  
Complement activation is central to the initial injury. The major 
mechanism of complement-induced injury is via the membrane attack complex 
(C5b-9). In addition to mediating complement-dependent lysis, sublytic 
concentrations of C5b-9 can also activate mesangial cells leading to release of 
various inflammatory mediators (oxidants, proteases, prostaglandins, growth 
factors and cytokines) and components of extracellular matrix [11, 12]. Injection 
of C6 deficient PVG rats that are unable to assembly C5b-9 with anti-thymocyte 
serum results in marked reduction in mesangiolysis with a decrease in 
macrophage infiltration, mesangial cell proliferation and ECM accumulation 
[13],[6].
Nitric oxide (NO) can be toxic to cells by causing nitrosylation of Fe-S 
groups of non-heme enzymes inhibiting mitochondrial respiration and in the 
setting of reactive oxygen species may form the highly toxic reactive nitrogen 
species, peroxynitrite. NO is synthesized from l-arginine by nitric oxide 
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synthase (NOS). In the anti-Thy1.1 model, the expression of the inducible 
isoform of the enzyme (iNOS) is upregulated at a very early stage, peaking 
within 1 hour [14]. The majority of iNOS positive cells in the first 24 hours are 
infiltrating neutrophils or macrophages.
Basic fibroblast growth factor (bFGF) is released by the injured 
mesangial cell and may lead to further injury by stimulating more NO production. 
Treatment with anti-bFGF antibody ameliorated initial mesangiolysis and 
prevented microaneurysm formation, resulting in less mesangial cell 
proliferation and less ECM deposition. 
Most of the infiltrating cells after initial injury are neutrophils and 
macrophages. However, many of the neutrophils rapidly undergo apoptosis and 
neutrophil depletion studies have shown that these cells play only a minor role. 
Infiltrating macrophages may produce both NO and reactive oxygen species 
mediating mesangiolysis. In addition to partly mediating the initial 
mesangiolysis, macrophages at later time points produce growth factors and 
cytokines that may contribute to mesangial cell proliferation and accumulation 
of mesangial matrix. 
Phase 2: Mesangial cell response to injury  
In the initial progress of injury, most descriptive studies describe the 
mesangial cell number to be reduced by up to 90%. Morita et al. in their studies 
about mesangiolysis in 1983 and 1998 described that the initial injury of 
 15
mesangiolysis with capillary expansion frequently advances to a mesangial 
balloon and less frequently to a glomerular aneurysm (Fig. 2,3). A fully 
developed mesangial balloon comprises an entire glomerular lobule. The 
folding pattern of the GBM is more or less totally lost, leading to large globular 
structures that are smoothly encircled by the GBM, followed by a layer of 
attenuated podocytes; microvillous surface transformation and areas with foot 
process effacement are frequent in such podocytes. In the case that individual 
infoldings of the GBM are maintained, they contain properly differentiated 
podocyte foot processes. Inside the balloons, very few capillaries are 
encountered, most of them without any association to the GBM. Otherwise, 
these balloons are filled with a fluid-rich tissue containing different amounts of 
star-shaped cells; collagen fibers are sparse. Between glomeruli with a largely 
preserved folding pattern of the GBM and those with mesangial balloons, a 
continuous spectrum of intermediates is encountered. Glomerular aneurysms 
are comparably rarely found and only in early stages. They are blood-filled 
lobular cysts with merging of mesangial and capillary spaces. Their walls 
consist of the expanded GBM (like that of a mesangial balloon) but is 
supplemented from the inside by cellular layers of collapsed and compressed 
capillaries. Proliferation is generally not seen inside such structures [3, 4]. 
Within a few days the glomerulus is repopulated. Initially the mesangial cell 
population is replaced by immigration of extraglomerular mesangial cells from 
the juxtaglomerular apparatus and hilar regions into microaneurysmal areas
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[18]. Cells from bone marrow are another replacer of repopulating mesangial 
cells. Takahito et al. transplantated bone marrow of tansgenic rats carrying 
enhanced green fluorescence protein (EGFP) to wild-type rats. After 
anti-Thy1.1 glomerulonephritis inducement, in the restored glomeruli, 11% to 
12% of the glomerular cells were derived from the transplanted bone marrow 
that could be tracked with a tag of EGFP (Fig. 4)[19].  
Figure 4. Bone marrow-derived EGFP+ cells lodged in the recipient kidney.
(A) EGFP+ cells fluoresced green in the recipient kidney. (B) The basement
membrane was stained with antilaminin polyclonal antibody followed by
Texas-Red-labeled secondary antibody to visualize the basic structure of the
kidney (red). (C) Green EGFP and red laminin were merged. (D) To identify
nucleated cells, the image shown in panel C was further merged with
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI)-stained nuclei.
Nucleated EGFP+ cells are sky-blue, whereas EGFP- cells are dark purple.
Slight background due to auto-fluorescence is observed in tubules.
Representative pictures are shown at a higher magnification Magnifications,
x400. (Ito T et. al. 2001)
In vitro, mesangial cells express a number of smooth muscle cell 
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associated proteins (?-SMA, calponin, certain myosin isoforms) and are 
contractile in response to a variety of agonists [20]. By contrast, ?-SMA is not 
expressed by the quiescent mesangial cell in vivo, but only when the mesangial 
cell is activated (Fig. 5). There is also increased expression of the cytoskeletal 
linking proteins, moesin and radixin, which bind to the actin filaments facilitating 
mirgration. The activated mesangial cell may also secrete interstitial collagens 
not normally found in mesangial matrix [21]. This altered cell phenotype has 
been termed a ‘myofibroblast’. Following immigration, proliferation of mesangial 
cells can be detected as early as day 2 and peaks on day 5 resulting in 
mesangial cell numbers which may be two to three times greater than normal 
baseline values [22]. By day 14, the glomerular cell number is returning to 
normal.
Figure 5. ?-SMA staing of activated mesangial cells (own data). A: glomerulus
of normal rat, B: glomerulus of rats on day 6 post OX-7 injection
A B
At the level of the cell cycle, the mesangial cell proliferation is associated 
with changes in the levels of positive cell cycle regulatory proteins as cyclins 
and cyclin-dependent kinases (CDK), and negative regulators of the cell cycle 
(cyclin kinase inhibitors). The proliferative mesangial cell decreases expression 
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cyclin kinase inhibitor p27 and increases expression and activity of cyclin 
A/CDK2 complex[23, 24].
Mediators of mesangial cell proliferation 
A wide variety of factors have been implicated in the mediation of 
mesangial cell proliferation (Fig. 6 [5]). 
Growth factors bind to receptors that may have intrinsic tyrosine kinase or 
serine/threonine kinase activity. Receptor activation leads to recruitment of 
adaptor molecules or kinases, and activation of downstream effector 
pathways, JAK-Stat pathway, SMADs, and others. Growth factor-induced 
activation of receptors and effector pathways can, however, be modulated by 
extrinsic factors, such as adhesion of cells to extracellular matrix (ECM). 
Effector pathways mediate the induction of transcription factors and 
consequent transcription of various genes, including cyclins, cyclin-dependent 
kinases (CDKs), CDK inhibitors, ECM proteins, and ECM-degrading 
proteinases. The outcome may include cell proliferation, antiproliferation,
differentiation, sclerosis, apoptosis, ECM deposition, and fibrogenesis. (Fig. 7)
The initial mesangial cell proliferation is mediated primarily by platelets
[25] and the release of preformed bFGF from injured mesangial cells. There is 
an early mark in influx of platelets, which peaks at 8 hours in this model. The 
mechanism by which platelets mediate mesangial cell proliferation is unclear; 
however, these cells carry an array of growth factors in their alpha and dense 
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Figure 6. Inhibitors of mesangial cell proliferation in the anti-Thy 1.1
model (Jefferson JA et.al.1999)
granules (platelet-derived growth factor (PDGF), basic fibroblast growth factor 
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Figure 7. Growth factor pathway for mesangial cell
proliferation mediators.
(bFGF), transforming growth factor-?  (TGF-? ), epidermal growth factor 
(EGF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1) 
and vascular endothelial growth factor (VEGF)) which may be released upon 
activation. bFGF is a known mitogen for mesangial cells in vitro and in vivo 
[24]. The later phase of mesangial cell proliferation is mediated primarily by 
platelet-derived growth factor (PDGF). Both platelets and macrophages can 
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produce some PDGF, but the principal source of PDGF is the mesangial cell. 
There is also upregulation of PDGF receptor ?  (PDGFR-? ) mRNA and 
protein by mesangial cells which suggests that the proliferative effect is 
primarily modulated by autocrine fashion. Treatment with polyclonal 
anti-PDGF immunoglobulin in this model did not affect the initial mesangiolysis 
or macrophage infiltration, but resulted in 50% reduction in mesangial cell 
proliferation at day 4 and reduction in ECM accumulation [26]. Early 
proliferation at day 2 was not affected. Other mediators of mesangial cell 
proliferation, including endothelin-1 (ET-1) and angiotensin-2 have also been 
shown to be mitogenic for mesangial cells in culture [27, 28]. Furthermore, 
angiotension-2 is known to stimulate mesangial cell TGF-? 1 expression [24]. 
Antagonizing the effect of ET-1 with EAT receptor antagonist led to a 50% 
reduction in glomerular cell proliferation [29] and ACE inhibitors and 
angiotension-2 receptor antagonists can reduce mesangial cell proliferation 
and the subsequent ECM accumulation as well [30]. 
Phase 3: Deposition of extra-cellular matrix 
In human disease, mesangial cell proliferation is commonly associated 
with mesangial matrix expansion [31] and may progress to irreversible 
mesangial sclerosis and deterioration in renal function. Matrix accumulation is 
the result of an increase in synthesis of normal components of mesangial 
matrix such as type IV collagen, laminin and fibronectin, as well as interstitial 
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collagens (type I and III) not normally found in the glomerulus. This is 
accompanied by a reduction in the breakdown of mesangial matrix. In our 
model, focal increase in the expression of type I collagen and type IV collagen 
is evident as early as day 3. By day 14 there is increased mesangial matrix in 
50% of glomeruli with 10-20% of glomeruli showing segmental sclerosis. Over 
the next four weeks, there is significant remodeling of mesangial matrix with a 
return to almost normal histology, although 20-30% of glomeruli show mild 
persistent increases in mesangial matrix in segmental areas [5] (Fig. 2, H-I). 
TGF-?  is central to the accumulation of ECM in this model. It upregulates 
the synthesis of ECM components as well as inhibits matrix degradation by 
decreasing the synthesis of proteases and increasing the production of 
protease inhibitors. There is also increased expression of TGF-ß type II 
receptor [32]. In the chronic model of anti-Thy 1.1 nephritis due to repeated 
injections of Thy-1.1 antibody, progressive glomerulosclerosis develops and is 
associated with persistence of TGF-ß expression [33]. Inhibition of TGF-ß 
activity using blocking antibodies results in a marked decrease in ECM 
accumulation and decreased proteinuria [34].
Phase 4: Resolution of mesangial injury 
Despite the initial massive mesangial injury and subsequent rebound 
mesangial cell proliferation, this model is characterized by resolution with 
return to almost normal morphology by 6-8 weeks. Following the initial 
 23
mesangial injury and loss of intact capillary loops, capillary repair begins at an 
early stage. Endothelial cell proliferation can be seen as early as day 1, 
peaking at day 5 and is present by day 10-14. Around day 5-7, angiogenic 
capillary repair occurs with the newly developing capillary entering the 
ballooned lesion from the vascular pole and connecting to peripheral capillary 
loops (Fig. 8, [6]). Endothelial cell number is increased between day 7 and day 
21, and returns to normal levels by increased endothelial cell apoptosis which 
starts at day 7 [35]. At the early stage, the glomerular endothelial cell 
proliferation is driven by bFGF from injured mesangial cells. At later stage, the 
proliferation is associated with increased VEGF expression mostly in 
podocytes [36]. 
The increase in mesangial cell number begins to fall by day 10, due to a 
combination of a decrease in mesangial cell proliferation and increased 
removal of mesangial cells. Decreased mesangial cell proliferation may be 
due to a decreased supply of growth factors such as PDGF and bFGF; 
however, PDGF is known to have an autocrine effect and can stimulate 
expression of PDGF and PDGFR-?  directly. Therefore, negative regulators of 
mesangial cell proliferation may exist. TGF-?  as an anti-inflammatory factor 
can inhibit mesangial cell proliferation. As proliferation ceases, glomerular cell 
number is reduced due to removal of unneeded mesangial cells. Apoptosis 
has been shown to be the main mechanism in returning glomerular cell 
number to normal in this model. Glomerular apoptosis is increased from day 7, 
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peaking days 10-14 and returning to baseline at day 28 [37]. 
By 6-8 weeks most glomeruli have returned to a normal mesangial 
volume partly due to an increased expression of collagenases and other 
proteases responsible for remodeling the mesangial matrix. 
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Figure 8. Revascularization process after glomerular injury. Patency of glomerular
capillary network was severely interrupted on day 5. Capillaries are scarce and
often found encircling the glomerular tuft (a). On day 8, capillary density in the
glomeruli was greater than on day 5. At this stage, tiny holes and small loops
(arrows), which are rarely found in control rats, are frequently encountered in the
capillary cast (b). By day 14, capillary density had restored to the normal state (c).
Magnified scanning electron micrographs (SEMs) of glomerular capillary casts
from rats on day 8 are shown (d to g). Two tiny holes with diameters around 1 m
can be seen in (d) (arrow). In addition, holes of various sizes are also prominent (e,
f, and g). Bar (a to c), 50 m; bar (d to g), 5 m. (Notoya M et.al.2003) 
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Vascular endothelial growth factor (VEGF) 
In 1983, Senger et al. [38] reported purification of a protein able to induce 
vascular leakage in guinea pig skin. This protein was named tumor vascular 
permeability factor (VPF). In 1989, Ferrara and Henzel and Ploüet et al. 
reported independently the purification to homogeneity and NH2–terminal
amino acid sequencing of an endothelial cell-specific mitogen, which they 
named, respectively, vascular endothelial growth factor (VEGF) and 
vasculotropin [39, 40]. Subsequent research revealed that VEGF, 
vasculotropin and VPF are mediated by the same molecule. This molecule, 
which was named VEGF, might play a key role in the regulation of 
physiological and pathological growth of blood vessels. Nowadays, compelling 
evidence indicates that VEGF is a fundamental regulator of normal and 
abnormal angiogenesis, which is a process of new blood vessel development 
from pre-existing vasculature. It plays an essential role in embryonic 
development, normal growth of tissues, wound healing, the female 
reproductive cycle, as well as a major role in many diseases [41] (Fig. 9). 
.
Vascular Growth Factor Isoforms 
The family of vascular growth factors includes placental growth factor 
(PLGF), VEGF-A, VEGF-B, VEGF-C and VEGF-D. VEGF-A is the major one. 
There are several splice variants of human VEGF-A, which includes: 121, 165, 
189, and 206 amino acids, every one comprising a specific exon addition. 
Whereas VEGF  and VEGF  are soluble secreted forms, VEGF  and 121 165 189
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Figure 9. VEGF family members and their receptors 
VEGF206 are mostly bound to the cell surface or to the extracellular matrix [41]. 
In rodents, the subunits are 1 amino acid shorter [42]. Compared to the other 
three isoforms in humans, VEGF165 is the most predominant protein produced 
by a variety of normal and transformed cells, though transcripts of VEGF121 
may be more abundant. VEGF165 is the major regulator of angiogenesis and is 
required for both vascular development as well as neo-angiogenesis in a 
variety of pathological conditions. It has been shown to regulate vascular 
permeability, endothelial cell migration, proliferation and survival. Transcripts 
encoding VEGF and VEGF121 189 are detected in the majority of cells and 
tissues expressing the VEGF gene [43]. VEGF is rarely expressed and has 206
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been detected only in fetal liver. And other splice variants of 145 and 183 
amino acids have also been described [44]. 
The isoforms are highly conserved between human VEGF 165 and rat 
VEGF 164 [45, 46]. Human VEGF 165 has been shown before to be 
biologically active in rats [47, 48]. 
Vasular Growth Factor Receptors 
Initial studies provide evidence for the existence of three receptors in the 
VEGF receptor family. They are VEGF receptor-1 (VEGFR-1, also known as 
Flt-1), VEGFR-2 (also known as KDR or Flk-1), and VEGFR-3 (also known as 
Flt-4). These receptors have the common properties of multiple IgG-like 
extracellular domains and tyrosine kinase activity. Endothelial cells also 
express additional VEGF receptors, Neuropilin-1 and Neuropilin-2 [49]. The 
major biological effects of VEGF on endothelial cells are exerted through its 
binding to Flt-1 and Flk-1/KDR. VEGFR-3 is specifically expressed on 
lymphatic endothelium. This pathway is important for lymphatic proliferation 
[50]. A cDNA codes an alternatively spliced soluble form of Flt-1 (sFlt-1). This 
sFlt-1 receptor binds VEGF with high affinity and is able to inhibit 
VEGF-induced mitogenesis [51]. 
Regulation of VEGF Gene Expression 
Oxygen tension has been shown to be a key regulator of VEGF gene 
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expression, both in vitro and in vivo. VEGF mRNA expression is induced by 
exposure to low O2 in a variety of normal and transformed cultured cell types, 
and also follows organ or tissue ischemia. Similar to VEGF, hypoxia has been 
proposed to play an important role in the regulation of VEGF receptor gene 
expression [52]. The transcription factors, hypoxia inducible factor-1?  (Hif-1
? ) and -2?  (Hif-2? ), are degraded by proteasomes in normoxia but 
stabilized in hypoxia. This pathway is dependent on the Von Hippel-Lindau 
gene product. Hif-1?  and Hif-2?  heterodimerize with the arylhydrocarbon 
nuclear translocator in the nucleus and bind the VEGF promoter/enhancer [53]. 
This is the key pathway expressed in most types of cells.  
Beside oxygen tension, several cytokines or growth factors may 
up-regulate VEGF mRNA expression. Epidermal growth factor (EGF), TGF-?,
platelet-derived growth factor (PDGF), insulin-like growth factor I (IGF-I), 
angiotensin-II, interleukin-1 (IL-1), interleukin-6 (IL-6) and keratinocyte growth 
factor 1 (KGF-1) can induce VEGF mRNA expression [54]. Cell differentiation 
has been shown to be another important reason for VEGF gene expression 
and specific transformation events also result in induction of VEGF expression 
[55]. The VEGF mRNA is up-regulated during the conversion of 3T3 
preadipocytes into adipocytes or during the myogenic differentiation of C2C12 
cells. Conversely, VEGF gene expression is repressed during the 
differentiation of the pheochromocytoma cell line PC12 into nonmalignant, 
neuron-like cells [55]. 
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Biological Effects of VEGF 
Vascular endothelial growth factor is a mitogen for vascular endothelial 
cells derived from arteries, veins, and lymphatics, but it is devoid of consistent 
and appreciable mitogenic activity for other cell types [56]. It stimulates 
endothelial cell proliferation and differentiation, increases vascular permeability, 
mediates endothelium-dependent vasodilatation, and supports vascular 
survival by preventing endothelial apoptosis [57]. In addition, VEGF induces 
plasminogen activator, plasminogen activator inhibitor-1 and interstitial 
collagenase, factors important in matrix remodeling. Furthermore, VEGF 
promotes expression of vascular cell adhesion molecule-1 (VCAM-1) and 
intercellular adhesion molecule-1 (ICAM-1) in endothelial cells [58]. This 
induction results in the adhesion of activated natural killer (NK) cells to 
endothelial cells, mediated by specific interaction of endothelial VCAM-1 and 
ICAM-1 with CD18 and VLA-4 very late antigen-4on the surface of NK cells. 
Besides endothelium, VEGF has also been reported to have regulatory 
effects on blood cells. It promotes monocyte chemotaxis and induces colony 
formation by mature subsets of granulocyte-macrophage progenitor cells [59]. 
Furthermore, VEGF may have an inhibitory effect on the maturation of host 
professional antigen-presenting cells such as dendritic cells [60], without 
having a significant effect on the function of mature cells. Some evidence has 
also been provided that VEGF is a fundamental regulator of differentiation of 
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the hemangioblast, the common precursor for endothelial and hemopoietic 
cells. It is the instructive signal that results in the differentiation of 
hemangioblasts into the endothelial lineage [61]. Vascular endothelial growth 
factor induces vasodilation in vitro in a dose-dependent fashion and produces 
transient tachycardia, hypotension, and a decrease in cardiac output. Such 
effects appear to be caused by a decrease in venous return, mediated primarily 
by endothelial cell-derived nitric oxide (NO) [62]. 
VEGF in renal pathophysiology 
In the kidney, VEGF expression is most prominent in glomerular podocytes 
and in tubular epithelial cells, while VEGF receptors are mainly found on 
preglomerular, glomerular, and peritubular endothelial cells. The role of VEGF 
in normal renal physiology is still essentially unknown, although the strategic 
localization of VEGF in the vicinity of the filtration barrier and its known effects 
on microvascular permeability have engendered the hypothesis that VEGF 
controls glomerular permeability in the normal adult kidney and induces 
proteinuria in pathologic conditions. The absence of prominent effects of VEGF 
blockade in normal experimental animals shows a limited function during 
homeostasis.  
Renal expression of VEGF and its receptors is consistently up-regulated 
in experimental animals and humans with type 1 and type 2 diabetes, 
especially in the early course of diabetes [63, 64]. Inhibition of VEGF 
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abolished the diabetes-associated glomerular hyperfiltration, glomerular 
hypertrophy, and urinary albumin excretion of type 1 diabetic rats [65] and 
attenuated the diabetes-associated increase in kidney weight, glomerular 
volume, abolished the increase in basement membrane thickness and 
creatinine clearance of type 2 diabetic mice [66] suggesting a deleterious role 
for VEGF in the pathophysiology of diabetic nephropathy. VEGF is required for 
glomerular and tubular hypertrophy and endothelial cell proliferation in 
response to nephron reduction, and loss of VEGF is associated with the 
development of glomerulosclerosis and tubulointerstitial fibrosis in the 
remnant kidney [67, 68]. No firm conclusions on the role of VEGF in minimal 
change or membranous glomerulonephritis can be drawn. Glomerular and 
tubulointerstitial repair in thrombotic microangiopathy and cyclosporin 
nephrotoxicity may also be VEGF-dependent. During recovery of anti-Thy 1.1 
nephritis up-regulation of VEGF mRNA in podocytes and the mesangial region, 
and of VEGFR-2 mRNA in the glomerular capillary walls was associated with 
endothelial cell proliferation [36, 69]. In accordance, administration of a 
VEGF165 antagonizing aptamer reduced glomerular endothelial cell 
proliferation and inhibited glomerular capillary repair resulting in glomerular 
sclerosis [48]. VEGF may be essential for glomerular repair in MPGN. 
Depressed VEGF synthesis resulting from podocyte injury may contribute to 
endothelial cell loss and favor the development of glomerulosclerosis. 
The paramount task of VEGF in the adult glomerulus appears to be the 
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stimulation of capillary endothelial cell growth and proliferation. This may be 
inappropriate in diabetic nephropathy where it contributes to glomerular 
hypertrophy and hyperfiltration, but may be an essential repair mechanism in 
glomerulonephritis. Similarly, tubular cells may respond to hypoxia or injury with 
the production of VEGF that stimulates proliferation of peritubular capillaries in 
order to overcome the tubular damage. In conclusion, VEGF is required for 
growth and proliferation of glomerular and peritubular endothelial cells. While 
deleterious in some, it may contribute to recovery in other forms of renal 
diseases.
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Hydrodynamics-Based Gene Transfection
The ability to introduce genes into tissues of an animal and to generate 
sufficient amounts of gene product is critical for medical science research. 
Because of the large capacity for synthesizing serum proteins and the 
involvement in numerous genetic and acquired diseases, the liver is a primary 
target organ for gene transfer. In last years, many routes for gene transfer into 
the liver have been attempted by using viral vectors. Recombinant viral 
vectors derived from human adenovirus are frequently used due to their ability 
to transduce a large number of liver cells. But there are safety concerns 
regarding the use of viral vectors. Alternatively, researchers have turned to 
cationic liposomes and polymers. Nonviral vectors are less toxic compared to 
the viral vectors, but they have lower efficiency of gene transfer. And, as a 
major side effect of this delivery system, they rapidly induce proinflammatory 
cytokines.
On the other hand, naked DNA has been considered as the simplest and 
safest gene delivery system. Recently, some scientists reported that high 
levels of foreign gene expression in mouse and rat hepatocytes can be 
achieved by rapid tail vein injection of a large volume of a solution containing 
naked DNA, the ‘hydrodynamics-based procedure’ [70, 71].  
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Method of Hydrodynamics-Based Gene Transfection 
The hydrodynamics-based procedure is performed by injecting a high 
volume (8-10% body weight, i.e. 15ml in a 150 gr rat) of a full-electrolyte 
solution containing naked plasmid via tail vein within a defined, short time (in 
our case, 1 ml/sec). Both injection volume and injection speed are critical for 
successful gene transfer. The studies from Liu et al. [70] demonstrated that 
gene transfer into mouse and rat liver via tail vein injection is easily applicable. 
Compared to mice, rats are more tolerant to the frequent phlebotomies 
required for monitoring blood parameters, and thus are more suitable subjects 
for several disease models. Though it is difficult to perform rapid tail vein 
injection in rats due to the thick skin that covers the rat tail vein and the fact 
that a high injection pressure against vascular resistance is required, 
hydrodynamics-based procedure can still be achieved by using a syringe with 
a winged needle equipped with an external tube. Hemostasis was seen at the 
injection site after applying pressure for 10 seconds. 
For tail vein injection and hepatic delivery route, hydrodynamic injection 
needs to overcome at least three physical barriers, (1) a spatial barrier 
between the site of injection (tail vein) and the targeted organ (liver); (2) the 
structural barrier of liver fenestrae that prevent the access of large molecules 
to hepatocytes and (3) the plasma membrane barrier of hepatocytes that limits 
the entry of hydrophilic molecules into the cytoplasm, especially large 
molecules like DNA, RNA, and protein [72]. 
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(1) A rapid injection of large bolus of solution into the animal results 
in an accumulation of the injected solution in the inferior vena 
cava. It exceeds the capacity of the heart to pump blood from 
the venous side of the circulation to the arterial side. The 
venous pressure attains a peak level at the end of injection and 
then falls rapidly to a level of 10-15mmHg above the baseline 
pressure [72]. Subsequently, high pressure causes a retrograde 
movement of the solution into the liver, the largest organ with an 
expandable structure and direct vascular connection to the 
inferior vena vava. Significant liver expansion can be observed 
when the hydrodynamic injection is performed via an abdominal 
incision. In addition, the color of the liver changes from normal 
reddish to whitish and then returnes to its normal color.  
(2) Liver capillaries are lined with endothelial cells. Approximately 
92-94% of the surface area of the liver endothelial cells is 
sealed preventing direct access of blood constituents to the 
hepatocytes [73]. The other 6-8% consists of pores with an 
average diameter of 100nm [74]. They are too small to allow 
large molecules to pass through. Therefore, the endothelium of 
the liver serves as a physical barrier for delivery of large 
molecules to the hepatocytes. Fraser et al. reported an 
enlargement of liver fenestrae when high pressure was used in 
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liver perfusion [75]. Zhang et al. [72] reported that in 
hydrodynamically treated animals, however, some of the 
fenestrae are enlarged and irregular. Pores as large as a few 
microns in diameter were seen. Various types of molecules that 
are different in structure and property can be delivered to the 
hepatocytes with similar efficiency suggesting that hepatic 
delivery by the hydrodynamic injection is a nonspecific process 
[72].
(3) Not only the liver endothelium, but also the membrane of the 
hepatocytes is affected by hydrodynamic-based injection. 
Scanning electron microscope micrographs of liver sections 
from hydrodynamically treated animals showed membrane 
defects (or pores), generated by the rapid injection of a large 
volume of solution. These membrane pores start to reseal 15 
seconds after injection. Most of the membrane pores reseal 
within 10 minutes. 
(4) Due to the very low diffusion rate of plasmid DNA in 
well-organized cytoplasm, transfer of DNA from cytoplasm to 
nucleus where gene expression initiates has been considered 
as an intracellular barrier for nonviral gene delivery. [76] Zhang 
et al. [72] injected identical copy numbers of GFP plasmids into 
cells with increasing volume. The GFP-positive cells increased 
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with increasing injection volume. Thus, a large volume of 
solution entering the hepatocytes due to the high extracellular 
pressure may have played a role in inducing a high level of 
transgene expression. 
The data presented above proved that hepatic transfer of naked DNA via 
the hydrodynamic pressure injection is a physical process and the barriers can 
be conquered. The mechanism of hydrodynamic-based transfection is similar 
to the mechanism of electroporation where membrane pores are generated by 
ion movement in an electric field, just that the hydrodynamics-based 
procedure generates membrane pores by a high pressured solution. 
Hydrodynamics-based gene transfection is a simple, convenient and 
efficient method to introduce and express exogenous genes in animals. It is 
extremely useful to test the functions of different genes. 
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Materials and Methods 
Experimental model and experimental design 
All our animal protocols were approved by the local government 
authorities. Animals were housed under standard conditions in a light, 
temperature and humidity controlled environment with free access to tap water 
and standard rat chow.  
Following gene transfer on day –1, anti-Thy1.1 mesangioproliferative 
glomerulonephritis was induced 24 hours later in all rats by injection of 1 
mg/kg body weight monoclonal anti-Thy1.1 antibody (clone OX-7; European 
Collection of Animal Cell Cultures, Salisbury, UK). On day 1, i.e. 48h after 
gene transfer, 500 μl blood were drawn from the tail vein to determine 
circulating VEGF levels. Living biopsies of the left kidney were performed on 
day 2. In 2 additional groups of rats (n = 5 each) sham gene transfer was 
performed by injecting 10 ml Ringer lactate solution per 100g body weight on 
day –1, followed by standard anti-Thy1.1 monoclonal antibody injection on day 
0. One of the groups was then treated with the vasodilator dihydralazine 
(Nepresol?, Teofarma, Valle Salimbene, Italy). The other group received 
carrier solution only. Rats were injected once daily i.p. with 10 mg/kg body 
weight dihydralazine diluted in Ringer lactate or Ringer lactate alone on d-1, 
d0 and d1 (Figure 10).
All animals were sacrificed on day 6 after induction of anti-Thy 1.1 
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nephritis, i.e. the time of maximal mesangioproliferative changes.
Prior to sacrifice, animals were placed in individual metabolic cages for 
24-hour urine collections. Urinary protein excretion was determined using the 
VITROS UPRO method (Ortho-Clinical Diagnostics, Rochester, NY, USY). 
The thymidine analogue 5-bromo-2'deoxyuridine (BrdU; SIGMA; 100 mg/kg 
body weight) was injected intraperitoneally at 4 hours before sacrifice (20mg 
BrdU per rat). 
Blood pressure was measured by the tail cuff method. In selected animals, 
the non-invasive measurements were verified by intraarterial blood pressure 
registration. For this 4-5 rats per group were anesthetized with Isofluran on 
day 1 after disease induction, and arterial blood pressure was measured by 
cannulation of the femoral artery using a Siemens Siroscript device (Siemens, 
Germany) followed by sacrifice. 
Plasmid DNA 
The plasmid pCAGGS-LacZ containing the CAG promotor 
(cytomegalovirus immediate-early enhancer/chicken ?-actin hybrid) was 
generated as described [77] and was used as a control vector. We constructed 
plasmid pCAGGS-VEGF by removal of the lacZ gene and insertion of human 
VEGF  cDNA between the two EcoRI sites. Human VEGF165 165 has a high 
homology to rat VEGF165 and has been shown to be highly effective in rats [47]. 
Plasmid DNA was prepared using the Qiagen Plasmid Mega Kit (Qiagen 
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GmbH, Hilden, Germany) within 2 days before use.
Method for constructing plasmid pCAGGS-VEGF: The lacZ gene was 
removed by incubating 1? g pCAGGS-LacZ DNA molecules with 10U EcoRI 
restriction enzyme (EcoRI, Fermentas GmbH, St. Leon-Rot, Germany) in a 
total volume of 50? l with its respective buffer as recommended by the 
supplier at 37?C for 2 hours to ensure complete digestion. 1% Agarose gel 
electrophoresis was employed to check the progression of a restriction 
enzyme digestion and to size fractionated DNA molecules. The 4790 bp 
fraction which is the pCAGGS vector was eluted from the gel by the QIAEX  
Gel Extraction Kit (Qiagen GmbH, Hilden, Germany). Human VEGF165 cDNA 
was inserted into the pCAGGS vector and transformation performed in 
competent E. coli. The transformed E. coli were stored at minus 80?C.
Purification of plasmid DNA: Transformed E. coli were inoculated in 500 ml 
LB medium and grown at 37°C for 12–16 h with vigorous shaking (180 rpm). 
Bacteria were harvested by centrifugation at 6000 x g for 15 min at 4°C and the 
pellets were resuspended in 50 ml of Buffer P1. After addition of 50 ml of Buffer 
P2, samples were gently inverted 4–6 times, and incubated at room 
temperature for 5 min. (The bacterial cells are lysed in NaOH–SDS (Buffer P2) 
in the presence of RNase A. SDS solubilizes the phospholipid and protein 
components of the cell membrane, leading to lysis and release of the cell 
contents.) After addition of 50 ml chilled Buffer P3, samples were mixed again 
and incubated on ice for 30 min. (The lysate is neutralized by the addition of 
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acidic potassium acetate (Buffer P3). The high salt concentration causes 
3-ketodihydrosphingosine (KDS) to precipitate, and the denatured proteins, 
chromosomal DNA, and cellular debris become trapped in salt–detergent 
complexes. Plasmid DNA, being smaller and covalently closed, renatures 
correctly and remains in solution.) After centrifugation at 20,000 x g for 30 min 
at 4°C, the supernatant containing plasmid DNA was removed promptly 
followed by another centrifugation step (20,000 x g for 15 min at 4°C). 
QIAGEN-tip 2500 were equilibrated by applying 35 ml of Buffer QBT, and 
allowed the column to empty by gravity flow. The supernatant contain plasmid 
was applied to the QIAGEN-tip and allowed it to enter the resin by gravity flow. 
Then the QIAGEN-tip was washed with a total of 200 ml of Buffer QC. The 
plasmid DNA was eluted with 35 ml of Buffer QF. (The cleared lysate is loaded 
onto a pre-equilibrated QIAGEN-tip by gravity flow. The salt and pH conditions 
of the lysate and the superior selectivity of the QIAGEN Resin ensure that only 
plasmid DNA binds, while degraded RNA, cellular proteins, and metabolites are 
not retained and appear in the flow-through fraction. The QIAGEN-tip is then 
washed with medium-salt buffer (Buffer QC) which completely removes any 
remaining contaminants, such as traces of RNA and protein, without affecting 
the binding of the plasmid DNA. Buffer QC also disrupts nonspecific 
interactions, and allows removal of nucleic acid-binding proteins without the 
use of phenol. The plasmid DNA is then efficiently eluted from the QIAGEN-tip 
with highsalt Buffer QF.) Plasmid DNA was precipitated by adding 24.5 ml 
 44
room-temperature isopropanol to the eluted DNA, then the solution was mixed 
and centrifuged immediately at 15,000 x g for 30 min at 4°C. The supernatant 
was carefully decanted. The DNA pellet was washed with 7 ml or 10 ml of room 
temperature 70% ethanol, and centrifuged at 15,000 x g for 10 min again. The 
supernatant was carefully decanted without disturbing the pellet. After 
air-drying for 10–20 min, the plasmid DNA was redissolved in 1 ml PBS and 
stored at 4?C.
Gene transfer 
Gene transfer using the hydrodynamic pressure method was performed 
as described [70]. In brief, male Wistar rats (purchased from Janvier, Le 
Genest-St-Isle, France), weighing 150-190g, were briefly anesthetized by 
isoflurane inhalation. 800 μg (high dose) or 100 μg (low dose) plasmid DNA 
diluted in 100 ml/kg body weight Ringer's solution (isotonic full electrolyte 
solution, room temperature) were injected via a winged 23 gauge needle into 
the tail vein at a speed of 1 ml/sec. During follow-up, we obtained blood 
samples from all rats for assessment of serum VEGF165 levels by tail vein 
puncture on day 1 after disease induction, i.e. 48 h after gene transfer. 
VEGF165 serum levels were quantified by ELISA (Quantikine human VEGF 
ELISA, R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany). In 
pCAGGS-LacZ treated animals, gene transfer was monitored by X-Gal 
staining of liver sections after sacrifice. 
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ELISA: The assay employs the quantitative sandwich enzyme 
immunoassay technique. A monoclonal antibody specific for VEGF165 had been 
pre-coated onto a microplate. Standards and samples were pipetted into the 
wells and any VEGF165 present was bound by the immobilized antibody. After 
washing away any unbound substances, an enzyme-linked polyclonal antibody 
specific for VEGF165 was added to the wells. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate solution was added to the wells 
and color develops in proportion to the amount of VEGF165 bound in the initial 
step. The color development was stopped and the intensity of the color was 
measured.
Liver histology and X-Gal staining 
Livers were harvested at sacrifice, i.e. days 1 and 6 after gene transfer, 
fixed in methyl Carnoy's solution, embedded in paraffin and processed for 
routine light microscopy. Five μm sections were stained with periodic 
acid-Schiff and hematoxylin and assessed for possible tissue injury due to the 
high pressure gene transfer. 
To monitor gene transfer in pCAGGS-LacZ treated animals, parts of four 
different liver lobes were embedded in Tissue-Tek O.C.T compound (Sakura 
Finetek, Zoeterwoude, The Netherlands) and frozen in methylbutane on dry 
ice. Eight μm sections were cut and placed on glass slides (SuperFrost Plus, 
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Menzel-Gläser, Braunschweig, Germany). Slices were fixed in 1% 
glutaraldehyde at room temperature for 10 min, then washed 2 x 5 min in PBS 
and incubated with the X-Gal staining solution containing 1mg/ml X-Gal 
(Invitrogen, Carlsbad, CA, USA), 100 mM sodium phosphate, pH 7.3, 1.3 mM 
MgCl , 3 mM K Fe(CN) , 3 mM K Fe(CN)2 4 6 3 6, at 37°C for 4 h in a humid chamber 
followed by counterstaining with Eosin. 
The ?-galactosidase enzyme catalyzed the hydrolysis of X-gal 
(5-bromo-3-indoyl-?-D-galactopyranoside), a ?-galactoside. Following fixation 
and incubation with the X-gal substrate, cells transfected with a 
?-galactosidase expressing plasmid appeared blue. These blue cells could be 
easily visualized by light microscopy. 
Renal morphology 
Tissue for light microscopy was fixed in methyl Carnoy's solution and 
embedded in paraffin. Four-micron sections were stained with the periodic 
acid-Schiff reagent and counterstained with hematoxylin. In the periodic 
acid-Schiff-stained sections, the number of mitotic figures within 30 to 50 
glomerular cross sections was determined. Mesangiolytic changes were 
graded as described [48][45] using a semi-quantitative scoring system. All 
slides were evaluated by an observer who was unaware of the origin of the 
slides
Periodic Acid Schiff (PAS) Staining: When treated with periodic acid, 
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glycols are oxidized to aldehydes. After reaction with Schiff’s reagent (a mixture 
of pararosaniline and sodium metabisulfite), a pararosaniline adduct is released 
that stains the glycol-containing cellular components. 
1. Deparaffinize and hydrate to water.
2. Oxidize in 2% periodic acid solution for 30 minutes.
3. Rinse in distilled water.
4. Place in Schiff’s reagent for 60 minutes. 
5. Wash in lukewarm tap water for 5 minute.
6. Counterstain in Mayer’s hematoxylin solution for 4 minute.
7. Wash in tap water for 5 minutes.
?? ?????????????????????????????????????????? ???????? ???????
Immunoperoxidase staining
Four micrometer sections of methyl Carnoy's-fixed biopsy tissue were 
processed by an indirect immunoperoxidase technique. Primary antibodies 
included a murine monoclonal antibody (dilution 1:50; clone BU-1, Amersham, 
Buckinghamshire, UK) against BrdU containing nuclease in Tris-buffered 
saline; a murine monoclonal antibody (dilution 1:500; clone 1A4, DAKO Corp., 
Capinteria, CA, USA) to ?-smooth muscle actin; a murine monoclonal IgG 
antibody (dilution 1:500; clone ED-1, Serotec, Oxford, UK) to a cytoplasmic 
antigen present in monocytes, macrophages and dendritic cells; a murine 
monoclonal antibody to rat endothelial cells (JG-12) plus appropriate negative 
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controls.
To determine the glomerular areas occupied by endothelial cells, the 
immunostains for JG-12 were evaluated using a point-counting method. For 
this, a grid composed of 100 dots was superimposed on an average of 25 
consecutive glomeruli (magnification 600-fold) and the percentage of dots 
overlying stained areas were counted. 
For evaluation of proliferating glomerular endothelial cells, double 
immunostaining for BrdU and JG-12 using TSA-enhancement was used. 
Briefly, sections were first stained with the murine antibody against BrdU 
followed by a biotinylated secondary antibody and an immunoperoxidase 
procedure generating a brown colour product. Next, sections were incubated 
with the murine monoclonal anti-endothelial cell antibody (JG-12) followed by 
a biotinylated secondary antibody and an immunoperoxidase procedure 
generating a red colour product. TSA was used for enhancement. Total 
numbers of double positive cells were counted per glomerulus and an average 
of 30 glomeruli were evaluated. 
All slides were evaluated by an observer who was unaware of the origin of 
the slides. 
ABC Method: The procedure employs a biotinylated antibody and a 
preformed avidin-biotinylated enzyme Complex and has been termed the 
"ABC" technique. Because avidin has an extraordinarily high affinity for biotin 
(over one million times higher than antibodies for most antigens), the binding 
 49
of avidin to biotin is essentially irreversible. In addition, avidin has four binding 
sites for biotin, and most proteins including enzymes can be conjugated with 
several molecules of biotin. These properties allow macromolecular 
complexes (ABC's) to be formed between avidin and biotinylated enzymes. 
The first step of the procedure is to incubate the section with primary 
antiserum raised against the antigen of interest. Next, a biotin-labeled 
secondary antibody is added. This introduces many biotins into the section at 
the location of the primary antibody. The avidin: biotinylated enzyme complex 
(ABC) is then added and binds to the biotinylated secondary antibody. In the 
last step of the procedure, the tissue antigen is localized by incubation with a 
substrate for the enzyme.
TSATM: TSATM (Tyramide Signal Amplification) is a powerful technology 
that significantly enhances both chromogenic and fluorescent signals. The TSA 
Biotin System technology uses HRP (horseradish peroxidase) to catalyze the 
deposition of the biotin-labeled tyramide (amplification reagent) onto tissue 
sections or cell preparation surfaces that have been previously blocked with 
proteins. The reaction is quick and results in the deposition of numerous biotin 
labels immediately adjacent to the immobilized HRP enzyme. These labels can 
then be indirectly detected by chromogenic or fluorescence visualization 
techniques, with significant enhancement of the signal. Because the added 
labels are deposited proximal to the initial immobilized HRP enzyme site, there 
is minimal loss in resolution. Chromogenic visualization is accomplished 
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through the use of a streptavidin-enzyme conjugate, followed by the 
appropriate chromogen. Fluorescence visualization is possible by the use of a 
streptavidin-fluorophore conjugate. This signal amplification technique can be 
applied to both in situ hybridization and immunohistochemistry. 
Quantification of glomerular mouse IgG deposition 
To determine the amount of anti-Thy 1.1 antibody deposited in kidneys, 
the glomerular binding of mouse IgG was assessed. For this, frozen kidney 
samples of animals sacrificed on day 1 after anti-Thy 1.1 nephritis induction 
(VEGF n = 5, LacZ n = 6) were cut in 8 μm thin sections and air dried for 1 h, 
followed by fixation in acetone for 5 minutes, washing in 1 x PBS and 
application of a purified, FITC-conjugated rabbit anti-mouse immunoglobin 
antibody in a dilution of 1:30 (DAKO, Glostrup, Denmark). After washing in 1 x 
PBS, mean glomerular fluorescence versus tubular background 
autofluorescence was analyzed using laser scanning microscopy (Axiovert 
100M confocal scanning laser microscope, Carl Zeiss, Germany). The 
microscope was used in a FITC parameter setup using 488 nm wavelength 
excitation at 505-550 nm. 
Statistical analyses 
Data are presented as mean ? standard deviation. Statistical significance 
was evaluated using ANOVA and Bonferroni-T test. P-values below 0.05 were 
 51
considered statistically significant. 
Blood Pressure Measurement using the tail cuff method 
Blood pressure was measured by the Softron indirect blood pressure 
metre BP-98A (Softron Co. Ltd. Tokyo Japan). Therefore, rats were put into an 
incubator 20 minutes before data were collected to adopt to the environment 
and calm down. The environment was  quiet, dark and 37?C warm. All data 
were gotten from tail arteries when animals were awake and the sensitivity 
level of the pulse wave was set within the range from 2 to 4. For further details, 
see the publication from Ostendorf et al. [78].
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Results
Gene transfer by the hydrostatic pressure method leads to high serum 
levels of hVEGF  and clinical signs of biological activity. 165
In pilot studies VEGF165 serum levels peaked within 24 hours after gene 
transfer. However, in the context of the present study, measurements were 
performed at 48 hours, i.e. 24 hours after anti-Thy1.1-nephritis induction, to 
quantify VEGF levels at the time point of maximum mesangial damage. 
Measurements in animals that had received high doses VEGF plasmid 
showed VEGF serum levels of 762 ± 434 pg/ml versus < 30 pg/ml, i.e. below 
the detection treshold of the ELISA, in animals receiving control plasmid. In 
rats receiving control plasmid, successful LacZ gene transfer was evidenced 
in all LacZ-animals by X-Gal staining, (Fig.11) whereas all VEGF-animals were 
negative for X-Gal activity. No expression of LacZ activity was noted outside of 
the liver (data not shown). Biological activity of the human VEGF165 in rats 
could be observed macroscopically in most animals with high VEGF-serum 
levels within few hours after gene transfer. These animals exhibited facial 
swelling (Fig. 12) and an increase of body weight (24 hours after VEGF gene 
transfer: 185 ± 9g in VEGF-rats, n = 7, versus 171 ± 8g in LacZ-rats, n = 6, p = 
0.013). Two high-dose animals died within 48 hours of VEGF gene transfer, 
possibly related to pronounced hypotension as also observed in 
cardiovascular studies [79][55]. 
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Figure 11. Hydrodynamic pressure gene transfer method (own data) 
A=Rat liver 48 hours after 
gene transfer by 
hydrodynamic pressure 
(800 μg pCAGGS-LacZ 
i.v.). X-gal staining for 
beta-galactosidase activity 
(black) in frozen material. 
B=Rat liver 48 hours after 
gene transfer by 
hydrodynamic pressure 
(800 μg pCAGGS-hVEGF 
i.v.). Negative X-gal 
staining for 
beta-galactosidase activity 
in frozen material. C= 
VEGF-treated rat (left) and
its LacZ-treated littermate 
(right) 24 h after gene 
transfer. Marked edema 
and 8% increase in body 
weight in the 
VEGF-treated rat.
A
C
B
High dose VEGF165 gene transfer augments glomerular damage in 
anti-Thy1.1 nephritis. 
Wide dilation of glomerular capillaries was present in animals receiving 
the VEGF plasmid but not in LacZ-treated animals (Fig. 12). In addition, 
VEGF-treatment significantly increased mesangiolysis scores and proteinuria 
in comparison to LacZ-rats (table 1). Blood pressure was markedly lower in 
VEGF-treated animals when compared to the control group on days 0 and 1 
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Figure 12. High dose VEGF165 gene transfer augments glomerular damage in
anti-Thy1.1 nephritis (own data). PAS staining. Day 2: A = VEGF-rat, global
mesangiolysis with dilated capillaries. B = control LacZ rat, mesangiolysis
score 1-2. Day 6: C =  VEGF rat with persistent damage. D = control LacZ rat,
typical mesangioproliferative lesions. 
after disease induction, as determined by both the tail cuff method and 
intraarterial recording of systolic blood pressure (table 1). No difference in 
blood pressure persisted at day 6 in the two groups (table 1).   
Animals with high mesangiolysis induced by high dose VEGF also 
exhibited increased glomerular cell proliferation, as determined by 
BrdU-positive nuclei, as well as an increase in glomerular ED-1+ 
monocytes/macrophages on day 6 (table 1). Of note, no difference was noted 
in the number of mitotic figures per glomerular cross section (table 1), which 
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might suggest that at least some of the increase in BrdU-positivity was due to 
monocytes/macrophages incorporating BrdU at extrarenal sites and then 
migrating into the glomerulus. 
Staining for ?-smooth muscle actin in the glomerulus, a specific marker of 
activated mesangial cells [22][56], tended to be lower in the high dose VEGF 
group but failed to reach statistically a significant difference as compared to 
controls (table 1). 
Augmented glomerular damage after VEGF165 gene transfer is not due to 
altered anti-Thy1.1 antibody binding. 
Quantification of mouse IgG in glomeruli in frozen sections of 5 high-dose 
VEGF-treated rats and 5 high-dose LacZ-treated rats sacrificed on day 1 
revealed no significant difference of fluorescence intensity as determined by 
laser scanning microscopy (35 ± 7 vs. 40 ± 8 optical units, respectively; p = 
0.254) (figure 4). Scanning of glomeruli of normal rats without prior anti-Thy1.1 
antibody administration yielded a mean of 5.4 optical units. (Figure 13) 
Fifure 13. Anti-Thy1.1 antibody binding (white) (own data). Images of laser
scanning microscopy. A: high-dose VEGF-treated rat on day1 B: high-dose
LacZ-treated rat on day1.
A B 
 56
Systemic hypotension per se augments glomerular injury 
To investigate the role of VEGF-induced hypotension in glomerular 
damage, 5 rats were sham-transfected and then treated with the vasodilator 
dihydralazine or vehicle (Ringer's solution) from day –1 until d1 after anti-Thy 
1.1 nephritis induction. Transient hypotension per se, like after high-dose 
VEGF plasmid transfection, augmented and prolonged mesangiolysis, 
glomerular monocyte/macrophage influx as well as glomerular cell 
proliferation on day 6 (table 2). Expression of ?-smooth-muscle-actin in the 
glomerulus again tended to be lower in the dihydralazine group but failed to 
reach statistically significant difference as compared to controls (table 2). In 
contrast to high dose VEGF, dihydralazine treatment did not increase 
proteinuria on day 6 (table 2).  
Low dose VEGF165 gene transfer augments glomerular damage at day 2 
independently of hypotension 
Based on the above findings with dihydralazine we asked, whether less or 
non-hypotensive doses of VEGF might be of therapeutic benefit in early 
anti-Thy 1.1-nephrits. We therefore injected 5 animals with 100 μg VEGF 
plasmid (instead of 800 μg as used in the high dose experiments) or 100 μg 
LacZ plasmid. This yielded VEGF serum levels of 71 ± 29 pg/ml vs. <30 pg/ml 
in LacZ rats. This approach indeed avoided the VEGF-induced edema, weight 
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gain and severe hypotension. However, the animals receiving low dose 
VEGF-plasmid still exhibited borderline hypotension (103 ± 9 vs. 112 ± 7). 
More importantly, low dose VEGF gene transfer also significantly increased 
mesangiolysis on day 2 as compared to the control group (table 3), whereas all 
other glomerular parameters on day 6 were not affected by low dose VEGF 
plasmid (table 3). More importantly, none of the parameters assesed showed 
even a trend towards improvement (table 3). 
VEGF165 gene transfer does not lead to an increase in endothelial 
proliferation on day 2 or 6
Treatment with VEGF, independent of dosage, did not lead to an increase 
in the glomerular area occupied by endothelial cells, i.e. the area staining 
positively for the JG12 antigen, on day 6 (tables 1 and 3). Furthermore, double 
staining for the endothelial JG12 antigen and BrdU in glomerular cells on day 6 
did not show a significant increase of proliferating endothelial cells (tables 1 
and 3). Since BrdU could only be injected once in the rats, we also assessed 
glomerular endothelial proliferation by counting mitotic figures in endothelial 
cell locations as described previously [48][45]. On day 1 after disease 
induction mitotic figures in glomerular endothelial cells did not differ between 
those rats receiving high dose VEGF plasmid and rats injected with control 
plasmid (0.06 ± 0.02 endothelial mitotic figures per 100 glomerular cross 
sections in high dose VEGF rats vs. 0.06 ± 0.03 in control rats; p = n.s.). This 
 58
likely relates to the pronounced endothelial damage on day 1, which may 
offset any VEGF induced endothelial cell proliferation. Animals in the 
hypotensive control groups did not show any difference in JG12 expression or 
JG12/BrdU double positivity (table 2). 
 59
Table 1: Mesangiolysis scores (range 0-3), proteinuria, blood pressure and 
immunohistochemistry findings in rats with anti-Thy 1.1 nephritis receiving 
high-dose VEGF or high dose LacZ plasmid. “n.s.” = not significant 
VEGF-plasmid LacZ plasmid p versus 
VEGF-groupHigh dose High dose (n = 6) (n = 7) 
Systolic blood pressure 
[mmHg] 109 ± 8 n.d. -- Day –1 (tail cuff method) 62 ± 17 119 ± 8 (n = 6) <0.001- Day 0 (tail cuff method) 85 ± 4 117 ± 8 (n = 6) <0.001- Day 1 (tail cuff method) 90 ± 20 (n = 4) 116 ± 3 (n = 5) <0.05- Day 1 (intraarterial method) 131 ± 5 132±5 n.s.- Day 6 (tail cuff method) 
Mesangiolysis [score] 
- Day 2 2.1 ± 0.2 0.6 ± 0.6 <0.001
- Day 6 1.1 ± 0.5 0.4 ± 0.5 <0.05
Proteinuria day 5-6 [mg/d] <0.005142 ? 29 66 ? 41
ED-1positive 
cells/glomerular cross section
Day 2 5.1 ± 0.7 4.1 ± 2 (n = 6) n.s.
- Day 6 8.2 ± 2.3 5 ± 1.3 0.01
BrdU positive 
cells/glomerular cross section on 
day 6 
3.9 ± 0.8 2.3 ± 0.7 (n = 6) <0.005
Mitotic figures per 100 
glomerular cross sections on day 6 24 ± 6 27 ± 9 n.s.
?-smooth muscle actin 
positive area per glomerular cross 
section on day 6 (%) 
32 ± 12 38 ± 12 n.s.
Glomerular area staining 
positively for the JG12 antigen on 
day 6 (%) 
32 ± 6 32 ± 7 (n = 3) n.s.
Glomerular cell count of cells 
positive for both JG12 and BrdU on 
day 6 
29± 10 32 ± 4 (n = 3) n.s.
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Table 2: Blood pressure, mesangiolysis scores, proteinuria and 
immunohistochemistry findings in nephritic rats treated from day –1 to day 1 
after disease induction with either dihydralazine or vehicle. "n.s." = not 
significant
p versus 
dihydralazine-
group
Dihydralazine Vehicle 
(n = 5) (n = 5) 
Systolic blood pressure [mmHg] 
108 ? 7 113 ? 5 - Day –1 n.s.
67 ? 9 105 ? 8 - Day 0 <0.001
- Day 1 <0.00176 ? 6 109 ? 9 
- Day 2 n.s.100 ? 7 110 ? 8 
- Day 6 n.s.114 ? 7 (n = 4) 118 ? 8 
Mesangiolysis [score] 
2.0 ? 0.5 1.5 ? 0.3 - Day 2 n.s.
- Day 6 <0.0050.9 ? 0.3 (n = 4) 0.2 ? 0.1 
Proteinuria day 5-6 [mg/d] n.s.133 ? 56 (n = 4) 132 ? 42 
ED-1 positive 
cells/glomerular cross section
-   Day 2 3.7 ± 1 3 ± 1.5 n.s.
- Day 6 7.2 ± 0.7 (n = 4) 4.9 ± 0.9 <0.005
BrdU positive 
cells/glomerular cross section on 
day 6 
4.5 ± 0.3 (n = 4) 2 ± 1.3 (n = 4) <0.01
Mitotic figures per 100 
glomerular cross sections on day 6 31 ± 7 (n = 4) 19 ± 6 <0.05
?-smooth muscle actin 
positive area per glomerular cross 
section on day 6(%) 
33 ± 7 (n = 4) 39 ± 4 n.s.
Glomerular area staining 
positively for the JG12 antigen on 
day 6 (%) 
43 ± 8 (n = 4) 41 ± 7 n.s.
Glomerular cell count of cells 
positive for both JG12 and BrdU on 
day 6 
45 ± 11 (n = 4) 26 ± 13 (n = 4) n.s.
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Table 3: Effects of low-dose VEGF-gene transfer on systolic blood pressure, 
mesangiolysis, proteinuria and immunohistochemistry findings in rats with 
anti-Thy 1.1 nephritis. "n.s." = not significant 
Low dose Low dose 
LacZ-plasmid p versus VEGF-group VEGF-plasmid(n = 10) (n = 7) 
Systolic blood pressure [mmHg]
107 ? 6 (n = 8) 108 ? 9 (n = 5) -  Day –1 n.s.
- Day 0 p = 0.05 103 ? 9 112 ? 7 
- Day 6 n.s.120 ? 14 121 ? 9 
Mesangiolysis [score] 
1.6 ? 0.3 1.1 ? 0.6 - Day 2 <0.05
- Day 6 n.s.0.6 ? 0.5 0.8 ? 0.6 
Proteinuria day 5-6 [mg/d] n.s.60 ? 50 38 ? 30 
Mitotic figures per 100 
glomerular cross sections on day 6 22.8 ± 12.5 19.7 ± 8.2 n.s.
ED-1 positive 
cells/glomerular cross section 
-   Day 2 4.5 ± 1.8 4.0 ± 1.7 n.s.
- Day 6 3.7 ± 3.7 3.2 ± 3.4 n.s.
BrdUpositive 
cells/glomerular cross section on 
day 6 
2.5 ± 1.7 1.7± 0.8 n.s.
?-smooth muscle actin 
positive area per glomerular cross 
section on day 6(%) 
31 ± 11  24 ± 15 n.s.
Glomerular area staining 
positively for the JG12 antigen on 
day 6 (%) 
41 ± 8 46 ± 5 n.s.
Glomerular cell count of cells 
positive for both JG12 and BrdU on 
day 6 
38 ± 14 35 ± 18 n.s.
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Discussion
In the present study, we first established a gene transfer method which is 
simple, relatively non-invasive and safe. The hydrodynamic pressure method 
uses naked DNA, i.e. the most simple vector available. Using a large fluid 
bolus, the hydrodynamic pressure method usually results in transient 
transfection of the liver, with little gene expression elsewhere [70, 71]. It 
therefore avoids any direct manipulation of the diseased kidney, as occurs, for 
example, using other gene transfer methods such as intrarenal injection or 
electroporation of the kidney [80]. In the context of renal disease the 
hydrodynamic pressure method is applicable for secreted factors, such as 
VEGF165. Using the hydrodynamic pressure method, we achieved widespread 
hepatic expression of a control gene, LacZ and subsequently of human 
VEGF165. Biological activity of the transfected VEGF was evidenced by 
systemic edema and weight gain, which likely relates to systemic induction of 
capillary leakage. In addition, VEGF transfection resulted in hypotension, 
which again may relate to capillary leakage, but also to NO-mediated 
vasodilation [79]. 
The glomerulus is a well-developed capillary network and mesangial cells, 
fenestrated endothelial cells and podocytes are responsible for the glomerular 
capillary structure. In the rat mesangioproliferative nephritis model, endothelial 
cell damage is also found in glomeruli[47, 48]. In this context, we point out that 
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VEGF is essential for endothelial cell migration, proliferation and survival. 
Therefore we made the hypothesis that overexpression of VEGF165  would 
accelerate the healing process of anti-Thy1.1 nephritis. But contrary to our 
expectations, VEGF165 overexpression during early anti-Thy1.1-nephritis 
considerably augmented and prolonged rather than improved glomerular 
injury, leading to higher mesangiolysis, proteinuria and cell proliferation as well 
as persistent glomerular monocyte/macrophage influx as compared to 
nephritic control rats. Our findings are in contrast to those of Masuda et al. [47], 
who administered 100 μg/kg bw recombinant human VEGF165 to rats with 
combined anti-Thy 1.1 and Habu snake venom nephritis and observed 
accelerated restitution of glomerular capillaries in the rats receiving VEGF. It 
appears unlikely that the more dramatic mesangiolysis and endothelial 
damage achieved by combined anti-Thy 1.1 and Habu snake venom injection 
is responsible for these diverging results. Differences in the mode of VEGF 
administration also are an unlikely explanation, since Masuda et al. [47] 
administered their VEGF165 using intraperitoneal micro-osmotic pumps and 
thus, like our study, avoided rapid fluctuations and peaks in serum levels. 
However, it can not be fully excluded that the more constant 7 day VEGF 
exposure in the study of Masuda et al. [47] may exert different effects than the 
about 4 day and changing exposure in our study. Second, assuming a 
distribution of injected VEGF165 over the extracellular space, i.e. 20% of body 
weight, it can be estimated that Masuda et al. achieved serum levels of 50-200 
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pg/ml continuously, which would be comparable to our measured serum levels 
on day 1 (71 ± 29 pg/ml) in the lowdose group. Probably the most important 
difference between the two studies may relate to the timing of VEGF165
administration, namely days 2 to 9 after disease induction in the study of 
Masuda et al. [47] as opposed to day –1 to about day 3 in our study, which in 
turn may impair endothelial progenitor mobilization (see below). 
Which mechanisms might have accounted for the adverse effects of 
VEGF-transfection that were observed in the present study? For this, we first 
assessed the role of VEGF-induced hypotension using a control group of 
nephritic rats, which received equipotent doses of the vasodilator 
dihydralazine. These experiments confirmed that pronounced hypotension 
during the acute phase of mesangiolysis and endothelial damage indeed 
impaired the healing process and aggravated injury. However, systemic 
hypotension can not be the sole explanation for our findings, as we 
subsequently performed studies with 12.5% of the initial VEGF plasmid dose, 
which did not induce severe hypotension but still amplified glomerular damage 
in nephritic animals, albeit to a lesser degree. Consequently, the apparent 
discrepancy between our findings and those of Masuda et al. [47] likely relates 
to the timing of VEGF165 administration, i.e. following the acute phase or 
during acute mesangiolytic damage in our study. One mechanism by which 
VEGF might aggravate glomerular damage in the acute mesangiolytic phase, 
during which the maximum of endothelial damage also occurs [6], may be the 
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mobilization of hematopoietic progenitor cells. Thus, it has been shown that 
bone marrow derived precursor cells contribute to glomerular healing and 
restitution of both mesangial cells [19] and glomerular endothelial cells [81]. 
Given that VEGF acts as a chemoattractant for circulating endothelial 
progenitors, it is conceivable that the overexpression of VEGF165 in the liver 
prevented the formation of a VEGF gradient from the kidney which may impair 
the adequate homing of progenitors to damaged glomeruli.
Another possible mechanism that could explain these results is the 
absolute level of overexpressed VEGF165. As Eremina and Quaggin indicate in 
their review [82], reduction in glomerular vascular endothelial growth factor 
leads to the renal lesion of preeclampsia, whereas increased vascular 
endothelial growth factor levels lead to collapsing glomerulopathy and 
increased endothelial cell permeability during glomerular development[82]. A 
morphologic study proved that angiogenic glomerular capillary repair may 
occur by new capillary growth from glomerular vascular poles as well as 
capillary regeneration from the remaining endothelial cells in damaged lesions 
and intussusceptive capillary growth occurs during reconstruction of the 
glomerular capillary network, too [6, 35]. Maybe VEGF dependent endothelial 
cell migration, proliferation and survival is not only ‘VEGF dependent‘ but 
‘VEGF dosage dependent’. Applying the hydrodynamic pressure method we 
used for gene transfer, VEGF165 serum levels peaked at 24 hours after tail vein 
injection but rapidly declined thereafter with almost no detectable levels in 
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serum at day 4 after gene transfer. This may be due to quick elimination of 
human VEGF165 due to immune mechanisms. For certain, the endothelial cells 
in our model were exposed to high VEGF165 levels at early time points. In 
contrary, Masuda et al. [47] administered their human VEGF165 protein using 
intraperitoneal micro-osmotic pumps, which released VEGF165 continuously 
at a steady rate over seven days.
In summary, we demonstrate that both high and low hepatic 
overexpression of VEGF165 during acute mesangiolysis aggravates 
glomerular damage and impairs rather than augments the subsequent 
restitution of a normal glomerular architecture. Given that in human diseases 
characterized by mesangiolytic injury, for example renal allograft rejection or 
thrombotic microangiopathies, glomerular damage usually does not occur in 
defined phases, it may be impossible to separate glomeruli with later disease 
stages, in which VEGF might improve healing [47, 83] from those with acute 
injury, in which VEGF may exert the opposite effect. Our findings thereby raise 
important safety concerns in cases of systemic VEGF therapy. 
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Summary:
Introduction: Vascular endothelial growth factor (VEGF) regulates vascular 
permeability and endothelial cell proliferation. In the rat anti-Thy1.1 
mesangioproliferative nephritis we showed that inhibition of VEGF165 impairs 
glomerular endothelial repair [47, 83]. In a combined anti-Thy1.1 + Habu 
snake venom nephritis model, systemic administration of recombinant human 
VEGF165 from day 2 to day 9 accelerated glomerular healing [47, 83]. We 
now studied the effects of systemic overexpression of VEGF165 during 
glomerular endothelial damage in this model. Materials and Mwthods: 
Hepatic gene transfer was performed by tail vein injection of a human VEGF165
expression plasmid or LacZ control vector 24 hours prior to induction of 
anti-Thy1.1-nephritis. A dihydralazine treated control group with sham gene 
transfer was performed too. Intravital biopsies were performed on day 2, 
animals were sacrificed at day 6. PAS stained sections were evaluated for 
mesangiolytic lesions (score 0 = none, 1 = focal, 2 = global, 3 = glomerular 
microaneurysm). Blood pressure (tail cuff method) was measured at days -1, 0, 
1, 6. Proteinuria was determined on day 6.Results: 1: Rats receiving high 
dose VEGF165 (800 μg plasmid; serum levels at 48h 762 ? 434 pg/ml vs. <30 
pg/ml in LacZ rats) showed generalized edema and transient hypotension on 
days 0 and 1, whereas LacZ treated animals remained normotensive. 2. On 
days 2 and/or 6 after disease induction, mesangiolysis, glomerular cell 
proliferation and glomerular monocyte/macrophage infiltration was 
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significantly increased in high dose VEGF165 rats vs. LacZ rats. 3: Proteinuria 
on day 6 was 142 ± 29 mg/d (VEGF165) vs. 66 ± 41 mg/d (LacZ). 4: 
Aggravation of glomerular injury was not due to altered anti-Thy1.1 antibody 
binding after VEGF165 gene transfer. 5: A dihydralazine treated control group 
with sham gene transfer showed that systemic hypotension per se augmented 
glomerular injury. 6: Hepatic overexpression of 8-fold lower VEGF165 doses in 
anti-Thy1.1-nephritis also resulted in augmented damage on day 2 and failed 
to improve glomerular histology on day 6. Conclusions: VEGF165
overexpression during early anti-Thy1.1 nephritis augmented glomerular injury, 
possibly mediated by systemic hypotension and/or uncoordinated endothelial 
repair. These findings raise important safety concerns in cases of systemic 
VEGF therapy and concomitant mesangiolytic injury. 
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